Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP14 | P50281 | 13/20 | 0.66 |
| ▸ | MMP9 | P14780 | 12/20 | 0.66 |
| ▸ | MMP8 | P22894 | 9/20 | 0.66 |
| ▸ | MMP3 | P08254 | 8/20 | 0.66 |
| ▸ | MMP7 | P09237 | 4/20 | 0.66 |
| ▸ | MMP1 | P03956 | 12/20 | 0.55 |
| ▸ | MMP13 | P45452 | 14/20 | 0.54 |
| ▸ | MMP2 | P08253 | 9/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6402161 | 0.99 | MMP14 (0.65) | MMP14MMP9MMP8MMP3MMP7 | |
| SCHEMBL6095377 | 0.91 | MMP9 (0.54) | MMP14MMP9MMP8MMP3MMP7 | |
| SCHEMBL6096560 | 0.91 | MMP14 (0.56) | MMP14MMP9MMP8MMP3MMP7 | |
| SCHEMBL6096556 | 0.90 | MMP14 (0.54) | MMP14MMP9MMP8MMP3MMP7 | |
| SCHEMBL6095774 | 0.84 | MMP1 (0.54) | MMP14MMP9MMP8MMP3MMP7 | |
| Hydrochloric Acid SCHEMBL6466769 | 0.84 | MMP1 (0.53) | MMP14MMP9MMP8MMP3MMP7 | |
| SCHEMBL6095979 | 0.84 | MMP13 (0.66) | MMP14MMP9MMP8MMP3MMP7 | |
| SCHEMBL6094181 | 0.83 | MMP8 (0.58) | MMP14MMP9MMP8MMP3MMP7 | |
| SCHEMBL6097048 | 0.83 | MMP13 (0.54) | MMP14MMP9MMP8MMP3MMP7 | |
| SCHEMBL6099760 | 0.82 | MMP13 (0.48) | MMP14MMP9MMP8MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067670-B2 | Sulfamato hydroxamic acid metalloprotease inhibitor | WARNER LAMBERT COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-20050043533-A1 | Process for making alpha-substituted hydroxamic acids | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2004091549-A2 | PROCESS FOR MAKING ALPHA-SUBSTITUTED HYDROXAMIC ACIDS | PHARMACIA CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
| US-6800646-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6492367-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | G. D. SEARLE & COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6448250-B1 | INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 | G. D. SEARLE & COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-1157021-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000046221-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | MMP14, MMP12, MMP17 | MMP14 1/4885MMP9 7/4885MMP8 33/4885 |
| US-20050043533-A1 | Process for making alpha-substituted hydroxamic acids | HAAO, RIMKLA, ASPH | MMP14 340/4885MMP9 522/4885MMP8 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.